European Hematology Association Congress | Conference

Single-Agent Acalabrutinib Showcases Potential Practice-Changing Data in Relapsed/Refractory CLL

June 17th 2019

Chemotherapy-free treatment with single-agent acalabrutinib provided a statistically significant and clinically meaningful improvement in progression-free survival compared with physicians’ choice of standard therapy in patients with previously treated chronic lymphocytic leukemia.

Acalabrutinib Monotherapy Safe, Significantly Improves PFS in Relapsed/Refractory CLL

June 16th 2019

Among the most highly anticipated study results to be presented during the 2019 European Hematology Association Congress were those of the phase III ASCEND trial, which investigated the use of acalabrutinib monotherapy in patients with previously-treated chronic lymphocytic leukemia.

Ibrutinib Significantly Prolongs PFS in Early-Stage CLL

June 16th 2019

Ibrutinib monotherapy significantly improved event- and progression-free survival compared with placebo in treatment-naïve patients with early-stage, asymptomatic chronic lymphocytic leukemia.

Phase III BELLINI Data Showcase Safety Concerns With Venetoclax in Multiple Myeloma

June 16th 2019

Despite promising progression-free survival and response data with venetoclax in combination with bortezomib and dexamethasone, an increased number of deaths due to infection in the experimental arm marred overall survival findings in patients with relapsed/refractory multiple myeloma.

Dr. O'Brien on the Phase III ASCEND Trial in CLL

June 16th 2019

Susan M. O’Brien, MD, associate director for Clinical Services, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the phase III ASCEND trial in chronic lymphocytic leukemia.

New Macrophage Immune Checkpoint Strategy Shows Promise in AML and MDS

June 16th 2019

Hu5F9-G4 (5F9), a first-in-class antibody targeting CD47, used as monotherapy or in combination with standard azacitidine was well tolerated and provided deep and durable responses in patients with acute myeloid leukemia or myelodysplastic syndrome, according to findings from a phase IB study presented at the 2019 European Hematology Association Congress.

Dr. Roboz on the QuANTUM-R Trial in AML

June 16th 2019

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

Dr. Tedeschi on Frontline Ibrutinib for Older Patients With CLL

June 16th 2019

Alessandra Tedeschi MD, Department of Hematology, Azienda Ospedaliera Niguarda Ca' Granda in Milan, Italy, discusses the long-term findings of the phase III RESONATE-2 trial during the 2019 European Hematology Association Congress.

Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKT

June 15th 2019

Othman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.

Addition of Rigosertib Improves Azacitidine Benefit in Patients With Higher-Risk MDS

June 15th 2019

The combination of rigosertib and azacitidine demonstrated improved response rates over single-agent azacitidine in patients with higher-risk myelodysplastic syndrome, including patients naïve to a hypomethylating (HMA) agent and those who were refractory to HMAs.

Second-Generation FLT3 Inhibitors Are Future of Relapsed/Refractory FLT3-Mutant AML Treatment

June 15th 2019

Naval G. Daver, MD, discusses the data that support quizartinib so far, ongoing investigations with this drug in the frontline setting, and the potential for the agent to be approved by the FDA.

Frontline Ibrutinib Showcases Long-Term OS Benefit in Older Patients With CLL

June 15th 2019

Frontline therapy with ibrutinib was successfully administered for more than 60 months in patients with chronic lymphocytic leukemia aged 65 years and older and provided improved progression-free and overall survival compared with chlorambucil.

Imetelstat Provides Durable Transfusion Independence in Lower-Risk Relapsed/Refractory MDS

June 14th 2019

Imetelstat treatment may allow patients with debilitating anemia due to myelodysplastic syndrome to remain transfusion-free for extended periods of time.

Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma

June 14th 2019

The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.

Dr. Rule on the MabCute Study in Indolent Non-Hodgkin Lymphoma

June 14th 2019

Simon Rule, MD, PhD, Plymouth University Medical School, discusses results of the phase III MabCute study evaluating subcutaneous rituximab as maintenance after standard subcutaneous rituximab induction and maintenance in patients who have relapsed or refractory indolent non-Hodgkin lymphoma.

Dr. Chari on the INSIGHT MM Study on Multiple Myeloma

June 14th 2019

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL

June 17th 2018

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Sallman on APR-246 Plus Azacitidine in TP53-Mutant MDS and AML

June 17th 2018

David Sallman, MD, assistant member, Moffitt Cancer Center, discusses the combination of APR-246 and azacitidine as a treatment for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL

June 17th 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.

Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma

June 17th 2018

The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.